Compounded Semaglutide — Is It Safe?

Dr. Ben Synth investigated the booming compounded semaglutide market and uncovered hundreds of adverse event reports, alarming impurity levels, and dosing errors hidden in an unregulated gray zone. This series exposes the supply chain risks, mystery ingredients, and legal loopholes behind those cheaper weight-loss injections.Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTVThis content was created in partnership and with the help of Artificial Intelligence AIThis episode includes AI-generated content.

Ben Synth examines how the FDA's drug shortage exemption allowed compounding pharmacies to produce cheaper semaglutide alternatives during the Ozempic and Wegovy shortage, creating a billion-dollar gray market with serious safety risks, dosing errors, and regulatory gaps that left millions of patients navigating uncertain ground.Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTVThis content was created in partnership and with the help of Artificial Intelligence AIThis episode includes AI-generated content.

Ben Synth examines disturbing findings from Novo Nordisk testing: some compounded semaglutide samples contained 33% impurities, including formaldehyde, trace metals, and banned substances like BPC-157. We discuss supply chain risks, unvetted foreign suppliers, non-pharmaceutical grade ingredients, sterility failures, and fraudulent labeling that distinguish compounded versions from FDA-approved Ozempic and Wegovy.Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTVThis content was created in partnership and with the help of Artificial Intelligence AIThis episode includes AI-generated content.

Ben Synth examines the dangers of compounded semaglutide, a cheaper alternative to FDA-approved weight loss drugs like Ozempic and Wegovy. The episode covers over 600 adverse events reported to the FDA, including severe overdoses, hospitalizations, and life-threatening complications. Through detailed analysis of regulatory data and clinical reports, Ben explores dosing errors, quality control failures, and the risks patients face.Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTVThis content was created in partnership and with the help of Artificial Intelligence AIThis episode includes AI-generated content.